

GLOBAL INNOVATORS REPORT 2017



FOREWORD	03
KEY FINDINGS	04
INTRODUCING THE CLARIVATE ANALYTICS 2017 TOP 100 GLOBAL INNOVATORS	06
ON THE RISE	20
SEVEN-TIME CHAMPIONS	22
GOING GLOBAL	26
INDUSTRY BREAKOUT	35
MEDICAL MARVELS	38
SCIENCE AND SYNERGY	46
LAW FIRMS	50
SECRETS TO SUCCESS	54
QUANTIFYING SUCCESS	62
WHO WE ARE	64
THE NEED FOR SPEED	66

2017

TOP 100 GLOBAL INNOVATORS



In the modern global economy, innovation increasingly serves as the driver of economic development and prosperity. Across industries and geographies around the world, the speed, magnitude, and complexity of innovative output has never been greater. As we embark upon the fourth industrial revolution, and as markets everywhere become increasingly competitive, the most successful organizations are those that can bring a steady stream of innovation to their customers and stakeholders.

Yet innovation cannot thrive without effective legal protection of the investments that make it happen. The investment of time and resources in the research and development needed to make inventions, and to turn them into products or services, is a risky proposition. The costs can be high, success uncertain, and any payoff, if it comes at all, may be years away. Patents help make these investments happen.

For 3M, patents foster sustainable growth based on 3M's innovation engine. They enable 3M science to be applied to life and to impact the world around us in real ways every day. That is why 3M is so pleased to be recognized by Clarivate Analytics as a Top 100 Global Innovator and expresses its gratitude to Clarivate Analytics for this recognition.

3M congratulates each of the other Top 100 Global Innovators. Their continuing commitment to investments in the research and development needed to bring inventions to life, and to patent rights that protect those investments, will ensure that they continue to create the innovations that are so essential to their growth and long-term success, and to prosperity around the globe.

KEVIN RHODES
CHIEF INTELLECTUAL PROPERTY COUNSEL, PRESIDENT
3M INNOVATIVE PROPERTIES COMPANY



The 2017 Top 100 Global Innovators report is the latest in an annual series that stretches back to 2011. In these reports, we seek to identify the most innovative organizations around the globe and to recognize and celebrate their contributions to providing new solutions to existing and unmet future challenges for the betterment of individual lives and society as a whole.

The report is based on findings from patent data driven analysis using Clarivate Analytics proprietary data and analysis tools, including Derwent Innovation and Derwent World Patents Index (DWPI), to execute a tried and trusted methodology which has been verified through market validation over the years. The methodology examines the portfolio strength and quality of each organization through assessing not just volume of patenting, but success in obtaining granted patents, breadth of filing of inventions and external citations to the portfolio to arrive at a combined indicator score which is used to identify the Top 100 most innovative organizations globally.

This year's findings show that the Top 100 Global Innovators are truly an exclusive group which is at the cutting edge, with innovation of better quality and more global commercial potential and with more impact and influence in ongoing innovation than those organizations outside the club.

HOW DO WE ASSESS INNOVATION?

FULL DETAILS OF THE METHODOLOGY ARE GIVEN AT THE END OF THE REPORT

All organizations with 100 or more patent families containing a granted patent are taken forward for assessment of three further factors.

The conversion rate of patent applications to granted patents is assessed as a measure of innovation quality.

The breadth of filing of inventions is measured to determine the perceived global market value of innovation.

Citations to patents are counted to assess the impact of foundational innovation on which later inventions are built.

QUALITY OVER VOLUME

The 100 organizations that make up the 2017 Top 100 Global Innovators continue to show characteristics that separate them from the crowd and demonstrate the true value of investing in innovation as a means to build sustainable development.

Looking globally, there has been an increase of 11.9 percent in the volume of new inventions published over the previous five years this year compared to last year. However, for the Top 100, that increase was only 2.4 percent. Top 100 innovators are filing less.



IT'S NOT HOW MUCH YOU PATENT, IT'S HOW GOOD THE INNOVATION IS."

Comparing the number of inventions containing granted patents over the same period shows that, globally, there has been only a 3.4 percent increase from last year to this year. By contrast, for the Top 100, that increase is 5.7 percent. The Top 100 Global Innovators have been more successful in obtaining full patent rights to their innovation than others. This could be due to a number of factors including drafting of higher quality applications, investing more in pre-filing searches or working harder to demonstrate the value of the innovation during the grant process.

At any rate, improved success in obtaining granted patents is linked to higher quality innovation and shows that the quality of innovation coming

from the innovation leaders is higher than the rest. It's not how much you patent, it's how good the innovation is. That comes from investing in the tools and processes that enable those filings to stand on their own.

BEING GLOBAL MATTERS

Not only are the Top 100 more focused on quality of innovation, they also demonstrate enhanced global commercialization value of that innovation. For the most important inventions that have global appeal, an organization is likely to seek wide protection in many territories.

Determining the number of inventions that are filed in the key global markets of US, Europe, Japan and China, or "quadrilateral" patent families, provides a measure of the value and importance of the portfolio of an organization.

For the 2017 Top 100 Global Innovators, the value of that measure has increased by 3.7 percent this year compared to last. If we also compare the average number of quadrilateral families in the patent portfolios for the Top 100 compared to other organizations globally, the contrast is stark; Top 100 innovators have 5.3 times as many quadrilateral families in their portfolio compared to the global average.

Clearly, the 2017 Top 100 Global Innovators are more successful in developing innovation with global market potential than those outside the Top 100.

STANDING ON THE SHOULDERS OF GIANTS

If imitation is the sincerest form of flattery, then citation is the truest form of acknowledgement. Innovation that builds on previous work will refer back to that original work through the

citations listed either by the applicant or the examiner's search report. The greater the number of citations to an original piece of work, the more likely it is to be an important development which has attracted the attention of many others seeking to improve upon it.

By tracking citations in later published inventions, an independent external measure of the value of an organization's innovation may be made. That measure for the 2017 Top 100 Global Innovators again shows clear water between them and the rest.

As a whole, the Top 100 have shown an increase of 2.8 percent in the ratio of citations (excluding self-cites) to inventions during the previous five years for this year compared to last. The Top 100 continue to demonstrate that their innovation is not just better quality with more global commercial potential, but that it also has more impact and influence in ongoing innovation.

INNOVATION HEADS EAST


There is a clear shift in the epicenter of innovation back from West to East. After a brief lapse into second place last year behind the US, the number of Top 100 Innovators from Asia has risen over 13 percent from 39 to 45 this year, again taking it above North America with 36 organizations.


Asian Top 100 companies have out-performed the Top 100 as a whole (excluding Asia) on all metrics which indicates they are producing higher quality innovation, seeking to commercialize that innovation more globally and creating more impactful innovation than both the remaining Top 100 Global Innovators and other organizations outside the Top 100.

INTRODUCING THE CLARIVATE ANALYTICS 2017 TOP














 \mathcal{M}











USA

2016


2015

SECTOR LIST

AEROSPACE & **DEFENSE**








AUTOMOTIVE









Company

DuPont



JPN


Nissan Motor













NEW FOR 2017









ONTHERIS

SIX COMPANIES ARE NEW HONOREES OF THE TOP 100 GLOBAL INNOVATORS LIST APPEARING FOR THE FIRST TIME SINCE THE PROGRAM BEGAN

Facebook showed a marked improvement in impact this year with a 44 percent increase in this metric over 2016. Average citations per invention over the last five years also rose 28 percent from 0.66 last year to 0.84 this year. Developments in full-screen, 360-degree video, and interactive ads for mobile and in e-commerce that allow users to complete transactions without leaving the platform have helped propel Facebook as one of the most innovative companies this year.

Fuji Electric has shown steady progress and growth in performance over the last seven years and has achieved sufficient growth, particularly in success and globalization metrics, to break through into the Top 100 for the first time this year. This is a tangible result of its open innovation program working with several Japanese Universities to promote joint research programs and internationally with the founding of research institutes in China, USA and Europe.

Hon Hai makes the list for the first time through improvements in both globalization and influence which indicates that it has been producing more impactful innovation over the last five years and is looking more internationally to protect its innovation in order to commercialize this more broadly. This is in line with its long-term research direction in key growth areas across the information technology sector, including telecommunications, consumer electronics, robotics and automation, optoelectronics and precision machinery, among others.

Molex extended the reach of its innovation this year as evidenced by a 45 percent growth in globalization this year compared to last year which sees it make the Top 100 for the first time. Recent innovation developments in the area of high-speed networking solutions such as its connected vehicle technology ecosystem with a new 10 Gbps automotive Ethernet backbone have borne fruit in Molex's inclusion in the Top 100 list this year.

VICHIA

Nichia has consistently filed its innovation widely and been highly cited by others working in light-emitting-diode technology, but this year has seen an uptick in Nichia's success in obtaining granted patent protection for its inventions resulting in its appearance in the list for the first time this year.

66

85 ORGANIZATIONS
HAVE SUSTAINED
THEIR INNOVATION
AT SUFFICIENTLY
CONSISTENT LEVELS."

/ESTERN DIGITAL

Western Digital has shown year on year growth in both globalization and impact to see it onto this year's list. Western Digital's investment in innovation has manifested itself this year in the recent announcement of the world's first microwave-assisted magnetic recording (MAMR) HDD and advancements in micro actuation and Damascene recording head technology.

TABLE 1: CHANGE IN REPRESENTATION OF THE 2017 TOP 100 GLOBAL INNOVATORS

NEW 2017	COUNTRY / REGION	INDUSTRY	
Asahi Glass	Japan	Chemicals & Cosmetics	
Casio	Japan	Hardware & Electronics	
Facebook*	USA	Software	
Fuji Electric*	Japan	Oil, Gas & Energy	
Furukawa Electric	Japan	Hardware & Electronics	
Hon Hai*	Taiwan	Hardware & Electronics	
ITRI	Taiwan	Institution & Govt Research	
Mitsubishi Electric	Japan	Household Goods	
Mitsui Chemical	Japan	Chemicals & Cosmetics	
Molex*	USA	Hardware & Electronics	
Nichia*	Japan	Chemicals & Cosmetics	
TDK	Japan	Hardware & Electronics	
Texas Instruments	USA	Hardware & Electronics	
Toray	Japan	Chemicals & Cosmetics	
Western Digital*	USA	Hardware & Electronics	

The large majority of organizations named in last year's Top 100 Global Innovators report are again recognized this year. 85 organizations have sustained their innovation at sufficiently consistent levels to justify inclusion again in this year's Top 100. These are joined by 15 newly honored Top 100 innovators in 2017 (Table 1).

SEVEN-TIME CHAMPIONS

THIRTY EIGHT OF THIS YEAR'S TOP 100 GLOBAL INNOVATORS HAVE CONSISTENTLY ACHIEVED RECOGNITION IN ALL SEVEN YEARS OF THE PROGRAM

THESE ARE THE
BEST OF THE
BEST AND EXHIBIT
CONSISTENTLY STRONG
PERFORMANCE."

These are the best of the best and exhibit consistently strong performance in successfully obtaining rights to their innovation, seeking wide protection and global markets for potential products and services based on that innovation and are recognized by their peers as creating leading innovation for others to build on.

Eighteen out of 38 of the seven-time champions are from USA. However, Japan dominates the charts with 14 champions representing the country. From an industry perspective, Hardware & Electronics are leading the way with 14 out of 38 making the cut and Chemicals & Cosmestics (6) trying to catch up closely behind.

ORGANIZATION	COUNTRY / REGION	INDUSTRY	AREA
3M Company	USA	Chemicals & Cosmetics	North America
Advanced Micro Devices	USA	Hardware & Electronics	North America
Apple	USA	Telecommunications	North America
Arkema	France	Chemicals & Cosmetics	Europe
Boeing	USA	Aerospace & Defense	North America
Broadcom	USA	Hardware & Electronics	North America
Canon	Japan	Hardware & Electronics	Asia
Commissariat à l'Energie Atomique	France	Institution & Govt Research	Europe
Dow Chemical Company	USA	Chemicals & Cosmetics	North America
DuPont	USA	Chemicals & Cosmetics	North America
Emerson	USA	Hardware & Electronics	North America
Ericsson	Sweden	Telecommunications	Europe
Fujitsu	Japan	Hardware & Electronics	Asia
General Electric	USA	Household Goods	North America
Hitachi	Japan	Hardware & Electronics	Asia
Honda Motor	Japan	Automotive	Asia
Honeywell International	USA	Hardware & Electronics	North America
Intel	USA	Hardware & Electronics	North America
LG Electronics	S Korea	Household Goods	Asia
LSIS	S Korea	Oil, Gas & Energy	Asia
Microsoft	USA	Software	North America
NEC	Japan	Hardware & Electronics	Asia
Nitto Denko	Japan	Manufacturing & Medical	Asia
NTT	Japan	Telecommunications	Asia
Olympus	Japan	Telecommunications	Asia
Panasonic	Japan	Household Goods	Asia
Qualcomm	USA	Hardware & Electronics	North America
Roche	Switzerland	Pharmaceuticals	Europe
Safran	France	Aerospace & Defense	Europe
Saint-Gobain	France	Manufacturing & Medical	Europe
Samsung Electronics	S Korea	Hardware & Electronics	Asia
Seiko Epson	Japan	Hardware & Electronics	Asia
Shin-Etsu Chemical	Japan	Chemicals & Cosmetics	Asia
Sony	Japan	Household Goods	Asia
Symantec	1104	Software	North America
	USA	001111010	
TE Connectivity	Switzerland	Hardware & Electronics	Europe
TE Connectivity Toshiba			Europe Asia





THIS YEAR'S FINDINGS SHOW THAT THE TOP 100 GLOBAL INNOVATORS ARE TRULY AN EXCLUSIVE GROUP WHICH IS AT THE CUTTING EDGE. THEY POSSESS BETTER QUALITY INNOVATION, MORE GLOBAL COMMERCIAL POTENTIAL AND MORE INFLUENCE ON ONGOING INNOVATION."




GOING GLOBAL

THE 2017 TOP 100 SAW A BURST OF INNOVATION WORLDWIDE, WITH ORGANIZATIONS FROM 11 DIFFERENT MARKETS

GLOBAL

The 2017 Top 100 Global Innovators are from three continents and originate from eleven countries & regions. Just two account for 75 percent of the organizations on the list: Japan and the US, making them the major innovation hubs of the world. Six of the others have been present on the list since the inception of the report series in 2011: France, Germany, Netherlands, South Korea, Sweden and Switzerland. These are joined by Taiwan for the fifth year in a row, China for the third time and Ireland and Finland again for the second year running.

FIGURE 1: COMPOSITION OF THE 2017 TOP 100 GLOBAL INNOVATORS



45 2017 40 2016 35 2016 25 2016

FIGURE 2: 2017 VS 2016 TOP 100 GLOBAL INNOVATORS - REPRESENTATION BY COUNTRY / REGION

Source: Derwent World Patents Index

JSA

France

10

5


0

78691

There is a significant shift towards Asia with 45 organizations from that region in the Top 100 this year compared to 39 last year, a 15% increase over last year. France maintains leadership again in Europe, although this has dropped from 10 organizations last year. China again appears on the list with a repeat honoree from last year, the telecoms multi-national, Huawei.

TABLE 3: 2017 VS 2016 TOP 100 GLOBAL INNOVATORS - CHANGE IN REPRESENTATION BY COUNTRY / REGION

COUNTRY / REGION	2017	2016		% CHANGE
Japan	39	34	↑	15%
USA	36	39	+	-8%
France	7	10	+	-30%
Germany	4	4	⇒	0%
South Korea	3	3	⇒	0%
Switzerland	3	3	⇒	0%
Netherlands	2	2	⇒	0%
Taiwan	2	1	↑	100%
China	1	1	⇒	0%
Finland	1	1	⇒	0%
Sweden	1	1	⇒	0%
Ireland	1	1	⇒	0%





ASIA


This year sees a return of the innovation hub back to the East with 45 of the Top 100 Global Innovators hailing from Asia compared to just 36 from North America and 19 from Europe. Asia has now taken the leading role in three of the last four years confirming their status as the global innovation powerhouse.

Japan is highly represented with 39 companies on the 2017 list, up from 34 in 2016. South Korea continues to feature with the same three companies as last year (LG, LSIS and Samsung). Taiwan has increased its presence this year with last year's recipient, Mediatek, being replaced by ITRI and Top 100 newcomer Hon Hai (Foxconn).

China makes a reappearance this year again with Huawei making the list following appearances in 2014 and 2016. As last year, Huawei again showed improved performance in globalization in line with its strategy to develop a "global response to global needs." ¹

Huawei's performance in impact is also improved significantly this year along with other Chinese innovators generally. Huawei is recognised as a tier 1 Chinese innovator in the recently published Clarivate Analytics 2017 Chinese Top 100 Innovators report (available here) which found that the overall combined influence metric of the Top 100 Chinese innovators grew by an impressive 60 percent over last year. This is a significant indication that the innovation being conducted in China is being picked up more widely and more often and is helping to drive innovation globally. China's performance in this area however still has some way to go to reach global standards. While China has an average ratio of 0.85 citations per patent family, the average ratio for the Top 100 Global Innovators is 1.12.

FIGURE 3: ASIAN REPRESENTATION COMPARED TO REST OF WORLD





THIS YEAR SEES A RETURN OF THE INNOVATION HUB BACK TO THE EAST WITH 45 OF THE TOP 100 GLOBAL INNOVATORS HAILING FROM ASIA."




NORTH AMERICA

After leading the regions for the first three years from 2011–2013, North America has slipped to second place again this year after a brief rally last year with 36 organizations compared to 39 last year.

Thirty-one of the 36 companies from the United States remain the same including last year's newcomers to the Top 100, Boston Scientific and Dolby Laboratories. The other first timer last year, University of California, is joined by Air Products, Bristol-Myers Squibb, Chevron, Corning, Interdigital and Lockheed Martin in slipping off the list this year.

The west coast, and specifically California, represents the geographical hot bed of USA innovation in terms of the most number of Top 100 innovators' origins and is dominated by Hardware & Electronics and Software companies (eight and six companies out of a total of 16 respectively).

FIGURE 4: BREAKDOWN OF USA TOP 100 GLOBAL INNOVATORS



Silicon Valley is well represented with AMD, Apple, Broadcom, Google, Intel, Marvell, Oracle, Qualcomm, Seagate, Symantec, Xilinx and Top 100 debutantes Facebook and Western Digital all making the cut this year. The West Coast region is rounded out by Amazon, Microsoft and Nike.

Surprisingly, the Mid West pips the East Coast for second slot with nine representatives on the Top 100 this year compared to eight from the East Coast. The Mid West innovators range across more diverse industries and are 3M, Abbott, Boeing, Delphi, Dolby, Dow, Emerson Electric, Johnson Controls and Top 100 newcomer Molex.

FIGURE 5: WEST COAST INDUSTRIES







FIGURE 6: MID WEST INDUSTRIES







EUROPE


With the ascendancy of Asia this year, Europe's share of the Top 100 has dropped from 22 representatives last year to just 19 this year.

Its country distribution has remained stable with one notable exception. France maintains its leadership in Europe, but with just seven representatives this year compared to 10 last year, all of Europe's losses are from there.


The three organizations missing this year are two research institutes, IFP Energies Nouvelles and CNRS, and the automotive supplier Valeo.

The loss of 66 percent of the three French research institutes named as a Top 100 innovator in 2016 may in part be a consequence of years of cuts in French research funding. In the first budget under President Macron, proposals to increase that funding by six percent in 2018 indicate an understanding of the long term consequences of underfunding of universities and research agencies.²

FIGURE 7: EUROPEAN REPRESENTATION OF THE 2017 TOP 100 GLOBAL INNOVATORS



² FRENCH GOVERNMENT PROPOSES BIG SCIENCE-SPENDING BOOST", BARBARA CASASSUS, NATURE, 29 SEPTEMBER 2017, HTTPS://WWW.NATURE.COM/NEWS/ FRENCH-GOVERNMENT-PROPOSES-BIG-SCIENCE-SPENDING-BOOST-1.22733






Other sectors with increased representation this year are Chemicals & Cosmetics going from nine firms last year to 12 this year and Software rising from five to six. In Chemicals & Cosmetics, half the companies (3M, Arkema, Dow, DuPont ³, Nitto Denko and Shin-Etsu) have consistently been recognized as Top 100 Global Innovators in each of the last seven years. These are joined by two firms from 2016 (BASF and Showa Denko) and four new organizations for 2017 (Asahi Glass [previously recognized in 2013 and 2014], Mitsui Chem [2015], Nichia [newcomer in 2017] and Toray [2015]).


Remaining sectors showed small downturns in representation, the largest being Automotive (from nine to seven firms) and Institution & Government Research dropping 40 percent from five organizations last year to just three this year.

TABLE 4: 2017 VS 2016 INDUSTRY COMPARISON OF TOP 100 INNOVATORS

INDUSTRY	2017	2016	% C	HANGE
Hardware & Electronics	34	29	1	17%
Manufacturing & Medical	14	15	4	-7%
Chemicals & Cosmetics	12	9	1	33%
Automotive	7	9	4	-22%
Household Goods	6	6	⇒	0%
Pharmaceuticals	6	7	4	-14%
Software	6	5	1	20%
Telecommunications	5	6	4	-17%
Oil, Gas & Energy	4	5	4	-20%
Aerospace & Defense	3	4	1	-25%
Institution & Government Research	3	5	+	-40%







Over the long term, Hardware & Electronics has historically been the largest sector followed by Manufacturing & Medical and Chemicals & Cosmetics as shown in Figure 8. Software, Automotive and Pharmaceuticals sectors have shown steady growth in representation consistent with increasingly smart technology in general, smart cars in particular and, amongst other developments, the rise in personal medicine. Telecommunications and Aerospace & Defense have shown long term contraction in the number of Top 100 Innovators over time which may indicate maturation and exploitation of existing innovation in these sectors.

66

HARDWARE &
ELECTRONICS TAKES
TOP SPOT, WITH 34
COMPANIES THIS YEAR.
THIS RISE SHOWS THE
GROWING IMPORTANCE
OF COMPUTING DEVICES
AND INFRASTRUCTURE
THAT PERVADES TODAY'S
WORLD."

³ THE RECENT COMPLETION OF THE MERGER OF EQUALS BETWEEN DOW AND DUPONT TOOK PLACE AFTER THE PERIOD OF ANALYSIS FOR THIS YEAR'S REPORT (2012–2016), BUT THE NEWLY FORMED DOWDUPONT WILL BE TREATED AS ONE COMPANY IN NEXT YEAR'S ANALYSIS.

MEDICAL MARVELS

THE PHARMACEUTICAL INDUSTRY IS DRIVE
BY INVENTION AND INNOVATION. IT IS ONE
OF THE FEW SECTORS WHERE R&D IS CENTRAL
TO SUCCESS AND ATTRACTING TALENT IS AS
CRUCIAL AS THE PATENTS THEY DISCOVER.

Innovation in the pharmaceutical industry, more than most, is about long-term investment and patience in realizing returns on that investment. It is perhaps therefore no surprise that six of last year's Top 100 honorees in the pharmaceutical sector remain on the list this year with the loss only of Bristol Myers Squibb.

Innovation means different things to different companies depending on their field(s) of activity. Indigenous R&D to develop unique approaches for disease treatment can take different forms from creating entirely new APIs to developing new formulations, combinations or uses. But for all six representatives from the pharmaceuticals sector of the Top 100, collaboration plays a significant part either through research funding of smaller enterprises or licensing deals to commercialize promising new therapies.

36

INNOVATION IN THE
PHARMACEUTICAL
INDUSTRY, IS
ABOUT LONG-TERM
INVESTMENT AND
PATIENCE IN REALIZING
RETURNS ON THAT
INVESTMENT."





THE ONES TO WATCH

Since its spin-out of Abbvie, Abbott is focused on breakthrough products in diagnostics, medical devices, nutrition and established pharmaceuticals outside of the U.S. Its patenting reflects this balance, which includes diabetes care, cardiovascular and neuromodulation within its medical devices business.

> The highest numbers of patents were unsurprisingly for either new formulations or diagnostics, with new delivery devices also showing well, as would be expected due to both the Cardio and Diabetes divisions. Amongst the diagnostics, one PCT application unveiled by Abbott in August 2017 appears to protect a new troponin test designed to identify heart attacks earlier in women. A study in The Lancet showed that the ARCHITECT STAT High Sensitive Troponin-I test successfully aided doctors in identifying people at risk for heart attack and helped physicians make treatment decisions about which people should stay in hospital. The test may greatly benefit women since their peak troponin levels are more difficult to detect. WO2017075268, jointly filed by Abbott, Emory University and Cardiorisk LLC is entitled "Troponin I and soluble urokinase receptor detection for determining the risk of cardiovascular disease".

For Merck KGaA and its subsidiaries, innovation this year was divided between new products and new formulations, combinations or uses, with the new compound patents being predominantly for small molecule entities. Acknowledging that innovation is a global reality and that a good portion of the future lies in Asia, Merck opened its first full-fledged drug development center in Asia in September, in Shanghai. Deal-making also formed an important part of activities. June this year saw an agreement to deepen relationships with F-Star Biotechnology to provide up-front research and development funding and which includes options to acquire five further programs.







In the case of Bayer, the company is diversified into Animal Health, CropScience, and Chemicals as well as pharmaceuticals. The company is showing results of the refocus on pharmaceuticals with recent investments into research and development with a return to the Top 100 Global Innovators from 2015 onwards. More than a third of its published patent applications in 2017 were for new chemical entities. Only one of these was for a biological, unlike many other large pharma companies, with WO2017087391 claiming a mAb acting as a coagulation stimulator for

use in treating hemophilia or other bleeding diseases. Bayer entered into a potential \$1.11 billion deal in November with Peptidream hoping the latter's popular therapeutic peptide discovery platform will help it discover novel lead structures in areas such as cancer and cardiology. Earlier in November, Bayer inked a potential \$1.55 billion deal with Loxo Oncology Inc., securing rights to two small-molecule candidates for the treatment of genetically defined cancers. Bayer will have the right to develop and commercialize all compounds resulting from the collaboration.

66

ONE PCT
APPLICATION
UNVEILED BY
ABBOTT APPEARS
TO PROTECT A
NEW TROPONIN
TEST DESIGNED TO
IDENTIFY HEART
ATTACKS EARLIER
IN WOMEN."

COLLABORATION

PLAYS A SIGNIFICANT PART THROUGH RESEARCH FUNDING OF SMALLER ENTERPRISES OR LICENSING DEALS."

Novartis, as well as having a focus on

the discovery and development of new drugs, also includes its Sandoz group of companies focusing on generics and biosimilars. This means that innovation is happening in different ways in the two parts of the company. For Sandoz, its patent focus is almost equally on new formulations and new crystal forms or salts of an originator product and on biosimilars with novel processes running a close third – with all patent publications being linked to a known drug product. This is much as one would expect from a generics/biosimilar company.

The company is obviously looking well into the future however, as one PCT application published this year claims a formulation of selexipag, developed by Actelion for the treatment of pulmonary arterial hypertension, which was acquired by J&J in 2017. Patent protection for selexipag is not due to expire for at least another 10 years, whilst the USA Orange book reports that selexipag has NCE and Orphan exclusivities until December 2020 and 2022, respectively. This could be an indication however that Sandoz intends to challenge some of the patents once the NCE and Orphan exclusivities have expired.

In a bold move, Novartis proposed in October 2017 buying radiopharmaceuticals specialist Advanced Accelerator

Applications SA (AAA) in a deal valuing the company at \$3.9 billion. The transaction would add the EU-approved neuroendocrine tumor therapy Lutathera (lutetium [177Lu] oxodotreotide) to the company's portfolio, as well as a new technology platform that Novartis said has potential applications across a number of early oncology development programs.

With a pair of drugs devoted to what Ionis Pharmaceuticals Inc. CEO Stanley Crooke called "systematically knocking off the remaining lipid risk factors" for patients facing cardiovascular (CV) trouble, the company and its subsidiary, Akcea Therapeutics, closed their potential \$1.6 billion deal [in February] with Novartis.

The Roche group is mainly focused on new drugs and, at least in part due to its Genentech subsidiary, there is a strong focus on Biological, especially antibody, products. Its IP portfolio reflects that focus with an almost even split between patents claiming new small molecules and new biological (macromolecular) entities. However, reflecting the need to more precisely target new drugs to subsets of an indication or to patients most likely to respond to the treatment, the number of diagnostic patents or applications published matches, if not exceeds, the number of "product" type patents.

An example is Roche's atezolizumab, approved in the USA in 2016 and in Europe during 2017 and marketed as Tecentriq®, for which nine patent families were published in the last year. Of these one claims the drug product, whilst five of the others include diagnostic claims and five include combination claims (some having both types of claims). WO2017151502, for example, provides methods of treating bladder cancer and methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist (e.g. atezolizumab or durvalumab).

In addition to inhouse development, Johnson & Johnson's patenting this year shows how larger pharmaceutical companies are handling their innovation in today's climate. Eight of the company's published patent applications that claimed new entities were filed by Actelion, the Swiss company acquired by J&J during 2017. Overall, new entity patenting for small molecules and biologics accounted for the biggest proportion of the patents published in 2017, although new formulations, new uses and combinations were also well represented. This included patenting for products that were in-licensed or codeveloped by J&J, such as canagliflozin, and daratumumab and for which initial product patents would have been filed by the originator companies, indicating that innovation doesn't end with the discovery of the new entity and its initial use.

 \otimes

INNOVATION DOESN'T END WITH THE DISCOVERY OF THE NEW ENTITY AND ITS INITIAL USE."








SCIENCE AND SYNERGY

COLLABORATION OF INSTITUTION AND GOVERNMENT RESEARCH IS ON THE RISE

This sector in the Top 100 Global Innovators has dropped from five organizations to three this year. The two organizations missing are French research institutes, IFP Energies Nouvelles and CNRS. These organizations have both seen a drop-off in success and impact metrics which have seen them miss out of the Top 100 for the first time in seven years.

Institution and Government research has become increasingly collaborative in recent years. For the three representatives of the Institution and Government research sector on the 2017 Top 100 Global Innovators list this year, this approach is reflected in the number of scientific papers which are internationally co-authored with other organizations. (Figure 9.)





Global Baseline

ITRI

Both CEA and Fraunhofer exceed the global baseline by some margin. Over the period from 2006–2017, 17.3 percent of papers globally are co-authored internationally; for CEA and Fraunhofer, that figure is 54.5 percent and 32.4 percent respectively. ITRI collaborates slightly less than the global average with 11.5 percent of papers published jointly during 2006–2017.

Fraunhofer

15 10 5

The major areas of research focus by scientific discipline are shown in Figure 10.

In addition, CEA specialises in a number of unique research areas not prominent at Fraunhofer or ITRI as shown below:

FOCUS RESEARCH AREAS UNIQUE TO CEA

SCIENTIFIC DISCIPLINE	# PAPERS 2006–2017
Astronomy & Astrophysics	7530
Physics, Particles & Fields	5229
Nuclear Science & Technology	4469
Physics, Nuclear	4061
Physics, Fluids & Plasmas	2261



Looking at the technology areas of most patenting activity within the Institution & Government research sector, we see in Figure 11 that the portfolios of CEA, Fraunhofer and ITRI are somewhat different. ITRI leads in digital computing, telephone and data transmission systems and memories, film and hybrid circuits; CEA shows strength in electro-(in) organics, semiconductors, scientific instrumentation and electrochemical storage; and Fraunhofer is focused on audio/video recording systems with some strength also in digital computing, scientific instrumentation and electro-(in)organics.



FIGURE 10: MAJOR AREAS OF RESEARCH FOCUS BY SCIENTIFIC DISCIPLINE. SOURCE: WEB OF SCIENCE





FIGURE 11: GOVERNMENT & INSTITUTION PATENT PORTFOLIO MIX FOR NEW INVENTIONS 2012-2016. SOURCE: DERWENT WORLD PATENTS INDEX



LAW FIRMS


THE ECOSYSTEM THAT INNOVATORS RELY UPON INCLUDES THE IMPORTANT ROLE THAT LAW FIRMS PLAY IN HOW INNOVATORS SECURE IP RIGHTS TO PROTECT THEIR INVESTMENTS

The innovation lifecycle is built on discovery and the Top 100 Global Innovators in this report have a deep commitment to investment in research & development to ensure a continual flow of new ideas which can then be protected with patents and commercialized through associated products and services. Although many of these organizations have their own IP groups, law firms play a major part in supporting the protection and commercialization of those ideas and helping innovators realize the full return on their investment.

So who are the law firms that partner with the Top 100 Global Innovators?

To answer that question, we took a look at the Top 100 companies and reviewed their patents to identify the major law firms working with these top innovators.

Using Derwent Innovation, for each Top 100 company, we identified the law firms working as the agent for their portfolio of patent families published over the five years from 2012–2016 ⁴ and totaled up the volumes for each law firm to give the overall count of patents assigned to Top 100 companies that each law firm handled. The Top 25 law firms representing the 2017 Top 100 Global Innovators are reported here for each geographic region.



66

LAW FIRMS PLAY
A MAJOR PART IN
SUPPORTING THE
PROTECTION AND
COMMERCIALIZATION
OF IDEAS AND HELPING
INNOVATORS REALIZE
THE FULL RETURN ON
THEIR INVESTMENT."

DATA WERE DRAWN FROM ALL PATENT DOCUMENTS MENTIONING A PATENT ATTORNEY IN THE DERWENT INNOVATION FULL TEXT COLLECTION OF OVER 111 MILLION RECORDS. NOT ALL RECORDS FOR ALL AUTHORITIE'S CARRY ATTORNEY DATA - FOR EXAMPLE, AROUND 70% ONLY OF PCT APPLICATIONS CONTAIN ATTORNEY DATA. DATA WERE NORMALISED BY LAW FIRM AND CORPORATE LAW DEPARTMENTS WERE EXCLUDED.

NORTH AMERICAN LAW FIRMS

Borden Ladner Gervais LLP	Canada
Craig Wilson & Company	Canada
Gowling WLG	Canada
Smart & Biggar/Fetherstonhaugh	Canada
Altis Law Group, Inc.	USA
Birch Stewart Kolasch Birch LLP	USA
Blakely Sokoloff Taylor Zafman LLP (now Womble Bond Dickinson)	USA
Dentons	USA
Fish & Richardson P.C.	USA
Fitzpatrick, Cella, Harper & Scinto	USA
Foley & Lardner LLP	USA
Global IP Counselors	USA
Harness, Dickey & Pierce	USA
Kilpatrick Townsend & Stockton LLP	USA
Knobbe Martens Olson & Bear LLP	USA
Lee & Morse P.C.	USA
Lee, Hong, Degerman, Kang & Waimey	USA
McDermott Will & Emery	USA
Novak Druce Connolly Bove + Quigg LLP	USA
Oblon, McClelland, Maier & Neustadt LLP	USA
Oliff PLC	USA
Schwegman Lundberg & Woessner P.A	USA
Staas & Halsey LLP	USA
Sughrue Mion PLLC	USA
Wenderoth Lind & Ponack	USA

ASIAN LAW FIRMS

Beijing Sanyou Intellectual Property Agency Ltd.	China
CCPIT Patent And Trademark Law Office	China
China Patent Agent (HK) Ltd.	China
China Science Patent & Trademark Agent Ltd.	China
China Sinda Intellectual Property	China
King & Wood Mallesons	China
Leader Patent & Trademark Firm	China
Linda Liu & Partners	China
Liu Shen & Associates	China
NTD Patent & Trademark Agency Ltd.	China
Shanghai Patent & Trademark Law Office LLC	China
Unitalen Attorneys At Law	China
Zhongzi Law Office	China
C&S Patent and Law Office	South Korea
FirstLaw P.C.	South Korea
Koreana Patent Firm	South Korea
NAM & NAM World Patent & Law Firm	South Korea
PanKorea Patent & Law Firm	South Korea
ROYAL Patent & Law Office	South Korea
Y.P. Lee, Mock & Partners	South Korea
Eikoh Patent Firm P.C.	Japan
Fukami Patent Office P.C.	Japan
Sakai International Patent Office	Japan
Shinjyu GLOBAL IP	Japan
Taiyo Nakajima & Kato	Japan

EUROPEAN LAW FIRMS

Brevalex	France
CABINET PLASSERAUD	France
Epping Hermann Fischer	Germany
Grünecker Patent- und Rechtsanwälte, PartG mbB	Germany
Herzog Fiesser & Partner	Germany
Hoefer & Partner Patentanwälte mbB	Germany
Kuhnen & Wacker Patent- und Rechtsanwaltsbüro	Germany
Maiwald Patentanwalts GmbH	Germany
MERH-IP, Matias Erny Reichl Hoffmann	Germany
Müller-Boré & Partner Patentanwälte PartG mbB	Germany
Pfenning, Meinig & Partner mbB	Germany
ТВК	Germany
Ter Meer Steinmeister & Partner	Germany
Viering, Jentschura & Partner mbB	Germany
Vossius & Partner	Germany
Winter, Brandl, Fürniss, Hübner, Röss, Kaiser, Polte	Germany
WITTEWELLER Patentanwälte	Germany
N.V. Nederlandsch Octrooibureau	Netherlands
Appleyard Lees IP LLP	UK
Boult Wade Tennant	UK
D Young & Co LLP	UK
Gill Jennings & Every LLP	UK
HGF Limited	UK
Hoffmann Eitle	UK
Marks & Clerk	UK

REST OF THE WORLD LAW FIRMS

Davies Collison Cave	Australia
FB Rice	Australia
FPA Patent Attorneys	Australia
Griffith Hack	Australia
Phillips Ormonde Fitzpatrick	Australia
Pizzeys Patent and Trade Mark Attorneys Pty Ltd	Australia
Watermark	Australia
Dannemann Siemsen Bigler & Ipanema Moreira	Brazil
AMICA LAW LLC	Singapore
Drew & Napier LLC	Singapore
Spruson & Ferguson (Asia)	Singapore




LAW FIRMS PLAY A MAJOR PART IN SUPPORTING THE PROTECTION AND COMMERCIALIZATION OF IDEAS AND HELPING INNOVATORS REALIZE THE FULL RETURN ON THEIR INVESTMENT."







FIGURE 12: COMPARISON OF PORTFOLIO LEGAL STATUS FOR TOP 100 GLOBAL INNOVATORS AND NON-TOP 100 COMPANIES IN THE SOFTWARE SECTOR



66

TOP 100 GLOBAL
INNOVATORS ARE
MORE COMMITTED
TO MAINTAINING
AND REALIZING
RETURNS ON THEIR
INNOVATION THROUGH
IP PROTECTION
THAN NON-TOP 100
COMPANIES."


Innovation is the process of realizing value from ideas. It starts with creativity and ends with a tangible means to generate commercial return. In between, the conversion of idea to practical reality requires application, dedication and perseverance. As Thomas Edison put it, "success is ten percent inspiration and ninety percent perspiration".

It follows then that successful innovators are not just good at creating new ideas, but excel in translating them into successful products, goods and services.

At the root of that process is the protection of ideas to allow the originator to obtain reward for their creativity safe from exploitation by others. Strong protection provides the right environment for the commitment and investment necessary to develop ideas to fruition.

That protection is afforded by patents. Successful innovators are those that succeed in obtaining strong patent rights across multiple markets for inventions that lay out new and influential ways of addressing unmet needs.

FIGURE 13: COMPARISON OF PORTFOLIO LEGAL STATUS FOR TOP 100 GLOBAL INNOVATORS AND NON-TOP 100 COMPANIES IN THE SOFTWARE SECTOR



To illustrate this, a comparison of some selected 2017 Top 100 Global Innovators with those outside the group has been conducted using the insights available from Derwent Innovation. As one of the fastest growing industry sectors in this year's Top 100 analysis, the Software sector was chosen and the six Top 100 companies (Amazon, Facebook, Google, Microsoft, Oracle and Symantec) compared to an equal number of firms by size outside the Top 100 (Adobe, CA Technologies, Intuit, Salesforce.com, SAP, and VMWare).

Comparison of the portfolio legal status for Top 100 and non-Top 100 software cohorts shows that Top 100 software companies have a higher proportion of their portfolios which are still active (between 73 percent and 91 percent with an average of 81.3 percent alive) than the non-Top 100 companies (ranging from 71 percent to 84 percent with an average of 77.8 percent alive). This shows that Top 100 Global Innovators are more committed to maintaining and realizing returns on their innovation through IP protection than non-Top 100 companies.



INNOVATION IS THE PROCESS OF REALIZING VALUE FROM IDEAS." Comparing the published application countries & regions for the Top 100 and non-Top 100 software groups, Top 100 software companies have 39 percent of their portfolio published in US, 17 percent as PCT patents, 13 percent as EP patents, 11 percent in China and then in 21 remaining countries & regions. Non-Top 100 companies have 80 percent of their portfolio published in US, seven percent as EP patents, three percent as PCT patents and then in 13 remaining countries & regions.

It is clear then that Top 100 software companies maintain a higher proportion of their IP rights and are seeking protection more widely in multiple jurisdictions for their inventions than the non-Top 100 companies and conform to the profile described of a successful innovator.

FIGURE 14: TOP 100 COHORT: TOTAL PATENT FAMILIES WITH BASICS PUBLISHED 2012-2016








FIGURE 15: NON-TOP 100 COHORT: TOTAL PATENT FAMILIES WITH BASICS PUBLISHED 2012-2016









QUANTIFYING SUCCESS

AT CLARIVATE ANALYTICS, WE USE A UNIQUE METHODOLOGY TO ANALYZE PATENT AND CITATION DATA ACROSS FOUR MAIN CRITERIA

66

FOR A PATENTED
INVENTION TO
BE VALUABLE, IT
MUST BE OF GOOD
QUALITY, HAVE A WIDE
MARKET AND LAY
THE FOUNDATIONS
FOR FURTHER
DEVELOPMENT
AND REFINEMENT."

Patents are a key measure of innovation; governments, academia and industry use them to inform policy decisions, track trends and for technological and commercial intelligence purposes. However straight counting of the volume of patents, while useful, is only part of the picture.

For a patented invention to be valuable, it must be of good quality, have a wide market and lay the foundations for further development and refinement. Therefore, in addition to counting the volume of inventions, the quality, globalization and impact of inventions should also be assessed.

The Clarivate Analytics Top 100 Global Innovators methodology analyzes patent and citation data across four main criteria: volume, success, globalization and influence using Clarivate solutions including *Derwent World Patents Index (DWPI)*, *Derwent Innovation* and *Derwent Patent Citations Index (DPCI)*.

Once an organization passes the volume stage gate, it is measured across the next three criteria: success, globalization and influence.

BALIZATION GL01

Protecting an invention in major world markets is an indication of the significant value a company places on its innovation and its intellectual property. The number of basic inventions that have quadrilateral patents in their patent families, according to the Clarivate Quadrilateral Patent Index, is calculated to create a ratio that shows which companies place a high value on their portfolios in major world markets. The quadrilateral patent authorities comprise the Chinese Patent Office, the European Patent Office, the Japanese Patent Office and the United States Patent & Trademark Office.

PROTECTING AN INVENTION IN MAJOR WORLD MARKETS IS AN INDICATION OF THE SIGNIFICANT VALUE A COMPANY PLACES ON ITS INNOVATION."

✓ Not all patent applications pass through the examination process and are granted. The success metric assesses the quality of innovation by measuring the ratio of inventions described in published applications (those patents which are filed and publicly published by the patent office but not yet granted) to inventions protected with granted patents over the most recent five years.

The impact of an invention "downstream" can be determined by looking at how often it is subsequently cited by other companies in the patenting of their inventions. Through the Derwent Patent Citation Index, citations to an organization's patents are counted over the most recent five years, excluding self citations.





THE NEED FOR SPEED

OUR PRODUCTS BELOW PROVIDE TRUSTED INSIGHTS AND ANALYTICS TO ACCELERATE THE PACE OF INNOVATION

ENT PATENTS CITATION INDEX

ш

For identifying possible partners, threats and ways to evolve a technology area Derwent Patents Citation Index (DPCI) is a value-added citation database with both patent and scholarly literature citations. These trace historical references on which an invention is built, as well as an invention's impact and future technologies that advance it.

Updated weekly, there are more than 11 million patent families and unique inventions that have been editorially enhanced for following forward and backward citations. With this insight, users can identify potential licensing partners, competitive threats and ways to evolve core intangible assets.

Within Derwent Innovation, DPCI is combined with the Derwent World Patents Index (DWPI) to provide the widest perspective of an invention and its impact and influence.

RWENT WORLD PATENTS INDEX

ш

For validity and infringement insight, unearthing existing prior art, identifying white space and performing competitive landscape research Derwent World Patents Index (DWPI) is the world's most trusted and authoritative source of global patent information, covering 50 patentissuing authorities. Bibliographic patent information is translated into English and editorially enhanced to bring clarity to a patent's true intentions.

A team comprising hundreds of editors, most with advanced degrees in their areas of specialization, incorporate value-added insight alongside original patent content to accurately understand the scope of an invention.

The world's first and only such patent search resource, with over 50 years of longevity and trusted by nearly 40 of the world's patent offices, DWPI is a unique and unparalleled resource for patent research.



PROTECTING AN INVENTION IN MAJOR WORLD MARKETS IS AN INDICATION OF THE SIGNIFICANT VALUE A COMPANY PLACES ON ITS INNOVATION."


Derwent Innovation powers the IP markets. Only Derwent Innovation provides the comprehensive, relevant, reliable information you need to save time, avoid risk, and create commercial gain. Don't worry about checking multiple sources, coping with foreign languages, or dealing with incomplete records. In Derwent Innovation access the most trusted global patent data and scientific literature with powerful capabilities to perform analysis and collaborate efficiently.


As the leader in global patent intelligence and collaboration, we could have rested on our laurels. Instead we have made significant investments in Derwent Innovation to continue to deliver customer value.

ERWENT DATA ANALYZER

Derwent Data Analyzer (DDA) is the industry leading analysis tool that transforms large amounts of IP data into actionable reports allowing for more strategic IP decisions. Easily analyze trends, profile competitors, avoid or uncover patent infringement, and identify strategic development opportunities. DDA is desktop software that offers a powerful interface for managing and extracting businesscritical insights from patent and scientific data within in-house or commercial databases. With its advanced analysis technology, DDA allows you to cut through masses of data to give you clear and definitive insights — at a glance.

TO LEARN MORE ABOUT DERWENT INNOVATION, DERWENT WORD PATENT INDEX AND OUR OTHER PATENT DATA SOLUTIONS TRUSTED BY MORE THAN 40 PATENT OFFICES WORLDWIDE, VISIT US AT HTTPS://CLARIVATE.COM/PRODUCTS/DERWENT-INNOVATION/CONTACT-US/





Built on the foundation of Web of Science, InCites uses the most thorough, accurate, and objective information available. With customized citation data, global metrics, and multidimensional profiles on the leading research institutions, you'll get comprehensive insight into your performance.

> The most trusted source of impactful research, Web of Science has unrivaled coverage of papers, books, conference proceedings, data sets and patents back to 1900. Using Web of Science, researchers can uncover the critical work in their field, and institutional leaders, funders and publishers can confidently measure comparative performance and develop world-class strategy using impact analytics and transparent metrics.

FOR A PATENTED INVENTION TO BE VALUABLE, IT MUST BE OF GOOD QUALITY, HAVE A WIDE MARKET AND LAY THE FOUNDATIONS FOR FURTHER DEVELOPMENT AND REFINEMENT."

Cortellis is the world's most comprehensive suite of solutions for life science professionals, providing unmatched content, intelligent search, state of the art analytics and powerful visualization tools. Cortellis delivers the unique insights you need to reduce risk and increase success in innovation.

BioWorld delivers actionable intelligence on the most innovative drug development science that drives the business, which funds the means to heal disease. With writers and editors stationed around the globe, BioWorld reports the breaking news — and provides key perspective — on hundreds of medicines in development, the companies behind those therapeutic candidates, the business development transactions that evolve the market, and the regulatory hurdles that both challenge and guard the process.

Clarivate Analytics and its logo as well as Web of Science, InCites, Derwent, Derwent Innovation, Derwent World Patents Index, Derwent Patents Citation Index, Derwent Data Analyzer, Cortellis, BioWorld, CompuMark, MarkMonitor and Techstreet are trademarks of the Clarivate Analytics group.



2017

TOP 100 GLOBAL INNOVATORS

#TOP100INNOVATORS ♥
TOP100INNOVATORS.COM
© 2018 CLARIVATE ANALYTICS

